Author

J. Pitts

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 2 Biochemistry· 1 Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Organism:Arabidopsis· 1 Assay:bulk RNA-seq· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

J. P. Bilello· 3 shared T. Cihlar· 3 shared V. Du Pont· 3 shared X. Lu· 3 shared D. Babusis· 2 shared D. P. Porter· 2 shared J. Y. Feng· 2 shared L. Rodriguez· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. P. Bilello

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

A conserved odorant receptor underpins borneol-mediated repellency in culicine mosquitoes

Y. Vainer, Y. Wang, R. M. Huff, D. Perets, E. Sar-Shalom, E. Yakir, M. Ghaninia, I. V. Coutinho-Abreu, C. Ruiz, D. Rajamanickam, A. Warburg, O. Akbari, P. A. Papathanos, R. Ignell, J. A. Riffell, , J. D. Bohbot

This study identifies a conserved odorant receptor involved in borneol-mediated repellency in culicine mosquitoes by mapping the neural pathway activated by borneol.

bioRxiv · Aug 1, 2023 · PreprintEvolutionary Biology

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys

R. L. Mackman, R. Kalla, D. Babusis, J. Pitts, K. T. Barrett, K. Chun, V. Du Pont, L. Rodriguez, J. Moshiri, Y. Xu, M. Lee, G. Lee, B. Bleier, A.-Q. Nguyen, B. M. O'Keefe, , T. Cihlar

bioRxiv · Apr 28, 2023Pharmacology & Toxicology

Diols and sugar substitutes in attractive toxic sugar baits targeting Aedes aegypti and Aedes albopictus (Diptera: Culicidae) mosquitoes.

H. Pullmann-Lindsley, A. Bartlett-Miller, J. Pitts

The paper evaluates diols and sugar substitutes for their toxicity to Aedes mosquitoes, finding several compounds significantly reduce survivorship and suggesting their use in attractive toxic sugar baits.

bioRxiv · Feb 9, 2023 · PreprintPharmacology & Toxicology

Anellovirus Structure Reveals a Mechanism for Immune Evasion

K. A. Swanson, S.-H. Liou, S. Delagrave, R. Hajiar, Y. Chang, N. Yozwiak, T. Ong, H. Rodgers, N. Cohen, Y. Zhang, N. Mukund Acharekar, S. Islam, L. Zaheb, C. Arze, H. Swaminathan, J. Pitts

This paper determines the structure of an anellovirus, revealing how its unique surface features enable immune evasion by hiding conserved epitopes and exposing diverse ones as decoys.

bioRxiv · Jul 1, 2022Biochemistry

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants

J. Pitts, J. Li, J. Perry, V. Du Pont, N. Riola, L. Rodriguez, X. Lu, C. Kurhade, X. Xie, G. Camus, S. Manhas, R. Martin, P.-Y. Shi, T. Cihlar, D. P. Porter, , J. P. Bilello

This study assesses the antiviral activity of remdesivir and GS-441524 against multiple SARS-CoV-2 variants, finding they remain effective against Delta, Omicron, and other variants.

bioRxiv · Feb 9, 2022Microbiology

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant

V. V. Edara, C. Norwood, K. Floyd, L. Lai, M. E. Davis-Gardner, W. H. Hudson, G. Mantus, L. E. Nyhoff, M. W. Adelman, R. Fineman, S. Patel, R. Byram, D. N. Gomes, G. Michael, H. Abdullahi, , M. S. Suthar

The paper compares antibody binding and neutralization against SARS-CoV-2 B.1 and B.1.351 variants in infected and vaccinated individuals, finding reduced titers but retained neutralization.

bioRxiv · Feb 20, 2021 · PreprintImmunology

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

A. J. Pruijssers, A. S. George, A. Schäfer, S. R. Leist, L. E. Gralinski, K. H. Dinnon, B. L. Yount, M. L. Agostini, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, K. L. Gully, D. R. Martinez, A. J. Brown, , T. P. Sheahan

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

bioRxiv · Apr 27, 2020Microbiology